New England Cancer Specialists | Scarborough, ME
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of atezolizumab (MPDL3280A) treatment compared with best supportive care (BSC) in participants with Stage IB-Stage IIIA non-small cell lung cancer (NSCLC) following resection and adjuvant chemotherapy, as measured by disease-free survival (DFS) as assessed by the investigator and overall survival (OS). Participants, after completing up to 4 cycles of adjuvant cisplatin-based chemotherapy, will be randomized in a 1:1 ratio to receive atezolizumab for 16 cycles or BSC.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Inclusion Criteria for Enrollment Phase
Inclusion Criteria for Randomized Phase - Women who are not postmenopausal (>/=12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of atezolizumab or BSC
Exclusion criteria
Exclusion Criteria for Enrollment Phase
Specific Exclusions for Pemetrexed Treatment
Exclusion Criteria for Randomized Phase
Primary purpose
Allocation
Interventional model
Masking
1,280 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal